U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07211165) titled 'Clinical Study on the Mass Balance of Clifutinib' on Sept. 22.
Brief Summary: To investigate the plasma total radioactivity PK characteristics of male healthy subjects after a single oral administration of [14C]Clifutinib, the distribution of total radioactivity in whole blood and plasma, and to determine the main excretion and metabolic pathways.
Study Start Date: Sept. 29
Study Type: INTERVENTIONAL
Condition:
Healthy Adult Male
Intervention:
DRUG: [14C]Clifutinib
The subjects are required to take the test drug on an empty stomach for at least 10 hours and without drinking water for 1 hour. After taking the drug, they should ...